What is the price target for ABOS stock?
12 analysts have analysed ABOS and the average price target is 7.14 USD. This implies a price increase of 130.99% is expected in the next year compared to the current price of 3.091.
ACUMEN PHARMACEUTICALS INC (ABOS) Forecast, Price Target & Analyst Ratings
NASDAQ:ABOS • US00509G2093
Current stock price
3.091 USD
-0.25 (-7.46%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ACUMEN PHARMACEUTICALS INC (ABOS).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 30, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.46
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$7.14
Upside
+ 130.99%
From current price of $3.09 to mean target of $7.14, Based on 12 analyst forecasts
Low
$4.04
Median
$7.14
High
$10.50
Price Target Revisions
1 Month
0.00%
3 Months
7.69%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for ABOS. The average price target is 7.14 USD. This implies a price increase of 130.99% is expected in the next year compared to the current price of 3.091.
The average price target has been revised upward by 7.69% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
88.33%
ABOS was analyzed by 12 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about ABOS.
In the previous month the buy percentage consensus was at a similar level.
ABOS was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-16 | BTIG | Maintains | Buy -> Buy |
| 2026-01-27 | BTIG | Maintains | Buy -> Buy |
| 2025-11-18 | B of A Securities | Maintains | Buy -> Buy |
| 2025-08-25 | B of A Securities | Maintains | Buy -> Buy |
| 2025-06-17 | Citigroup | Initiate | Buy |
| 2025-03-28 | UBS | Maintains | Buy -> Buy |
| 2025-03-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-15 | UBS | Maintains | Buy -> Buy |
| 2024-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-25 | Citigroup | Initiate | Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-12-12 | Deutsche Bank | Initiate | Buy |
| 2023-08-09 | Credit Suisse | Reiterate | Outperform -> Outperform |
| 2023-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-20 | B of A Securities | Reiterate | Buy |
| 2023-07-17 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-07-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-18 | Cantor Fitzgerald | Initiate | Overweight |
| 2023-03-28 | Credit Suisse | Maintains | Outperform |
| 2023-03-28 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-02 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-15 | Credit Suisse | Maintains | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 30, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.46
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 25.45%
- Number of Analysts
- 8
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.58%
Next Earnings Summary
ABOS is expected to report earnings on 3/30/2026. The consensus EPS estimate for the next earnings is -0.46 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.7M | 1.44M -15.29% | -100.00% | 26.928M | 71.706M 166.29% | 122.3M 70.56% | ||||||||||
| EBITDA YoY % growth | N/A | N/A | -16.395M | -41.206M -130.90% | -58.074M -34.79% | -108.059M -86.97% | -134.057M -17.66% | 28.187B 21,126.20% | 45.037B 59.78% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -7.81M | -7.91M -1.28% | -37.949M -147.53% | -42.101M -131.05% | -59.947M -34.84% | -105.903M -86.89% | -130.45M -14.43% | -118.872M 8.87% | -132.626M -11.57% | -69.392M 47.68% | -122.38M -76.36% | -113.096M 7.59% | -100.638M 11.02% | -31.968M 68.23% | 99.723M 411.94% | |
| Operating Margin | -459.41% | -549.31% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -373.73% | -44.58% | 81.54% | |
| EPS YoY % growth | N/A | N/A | -3.78 | -1.00 71.98% | -1.09 -1.89% | -1.61 -58.33% | -2.09 -22.12% | -1.68 19.55% | -1.49 11.60% | -2.20 -48.35% | -2.07 6.02% | -0.36 82.76% | 0.64 280.00% | 2.13 231.75% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.46 25.45% | -0.39 19.25% | -0.37 45.50% | -0.37 16.55% | -0.31 32.70% | -0.17 55.26% | -0.17 53.21% | -0.18 50.00% | -0.18 40.98% |
| Revenue Q2Q % growth | |||||||||
| EBITDA Q2Q % growth | -31.369M 20.65% | -29.549M 2.65% | -30.233M 27.53% | -29.274M -10.61% | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -29.574M 25.31% | -24.805M 18.32% | -23.29M 44.22% | -23.146M 12.70% | -17.717M 40.09% | -18.249M 26.43% | -18.797M 19.29% | -19.361M 16.35% | -19.941M -12.55% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
4.20%
EPS Next 5 Year
-3.90%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
653.18%
EBIT Next 5 Year
N/A
ACUMEN PHARMACEUTICALS INC / ABOS Forecast FAQ
When does ACUMEN PHARMACEUTICALS INC (ABOS) report earnings?
ACUMEN PHARMACEUTICALS INC (ABOS) will report earnings on 2026-03-30, after the market close.
What are the consensus estimates for ABOS stock next earnings?
The consensus EPS estimate for the next earnings of ACUMEN PHARMACEUTICALS INC (ABOS) is -0.46 USD and the consensus revenue estimate is 0 USD.
How many analysts have analysed ACUMEN PHARMACEUTICALS INC (ABOS)?
The number of analysts covering ACUMEN PHARMACEUTICALS INC (ABOS) is 12.